Exposing the “Second Skin” Scam: Medicare Fraud Charges Rock Wound Care Sector
In a case that has sent shockwaves through the wound care and podiatry communities, a Texas podiatrist and his business partner have been indicted for allegedly orchestrating one of the largest Medicare fraud schemes involving bioengineered skin substitutes to date.
Dr. David Jenson, a practicing podiatrist in The Woodlands, TX, and Néstor Refael Romero Magallanes, his business partner, are accused of submitting over $90 million in fraudulent Medicare claims and receiving more than $45 million in reimbursements through their company, Doctor’s Inc. The Department of Justice has charged the pair with conspiracy to commit health care fraud and aggravated identity theft, among other allegations.
The Core of the Scheme: “Second Skin” Exploitation
At the heart of the case is the misuse of high-cost, bioengineered skin substitutes—often referred to in clinical parlance as “second skin” products. These advanced wound care materials, such as amniotic or cellular tissue allografts, are FDA-cleared for complex, non-healing wounds like diabetic foot ulcers or venous leg ulcers. However, the treatment is only reimbursable under Medicare when medically necessary and properly documented.
Prosecutors allege that Jenson and Romero systematically billed Medicare for skin substitute applications that were neither medically necessary nor actually performed as documented. They often cited vague complaints such as “swelling,” “foot pain,” or “skin discoloration” as justifications for treatment, even when no chronic wound was present.
More troubling, the duo is said to have fabricated patient records and misrepresented to patients that their Medicare plans fully covered the procedures—when in fact, some of the billed services had already been flagged by Medicare as ineligible or questionable. Patients, many of them elderly or Spanish-speaking, were often unaware of the scope of the procedures or the financial ramifications of the claims submitted in their name.
Pattern of Deception, Despite Warnings
The indictment reveals that the alleged scheme persisted even after a clear warning. In early 2023, federal authorities reportedly issued a cease-and-desist communication to Doctor’s Inc. regarding billing irregularities. Rather than complying, Jenson and Romero allegedly continued their billing practices, attempting to disguise them through alternate business entities and falsified documentation.
According to the DOJ, multiple fictitious wound diagnoses were created to justify the skin substitute applications, and services were often reported as being provided by supervising physicians who were not present or affiliated with the patient’s care. In some cases, patients were never physically evaluated before billing was submitted for complex wound procedures.
The volume of applications billed is staggering: thousands of claims for expensive skin substitute treatments over a short time span, often for the same patient at an unsustainable frequency. The total amount billed—$90 million—makes this one of the largest fraud cases involving regenerative wound products on record.
Why This Case Matters to the Wound Care Community
The indictment has renewed scrutiny over the use and oversight of cellular- and tissue-based products (CTPs) in outpatient and podiatric care settings. While these products are clinically valuable when applied correctly, they’ve become a magnet for abuse due to their high reimbursement rates and limited auditing mechanisms.
In recent years, CMS and commercial insurers have raised concerns about CTP overutilization. Several skin substitute products have been subjected to increased prior authorization requirements, reimbursement limits, and tracking under quality improvement initiatives. This case could accelerate further regulatory tightening, potentially affecting legitimate providers who follow guidelines and treat truly chronic, non-healing wounds.
“What we’re seeing is not just financial fraud—it’s clinical fraud,” said one wound care specialist who asked to remain anonymous. “Overuse of these materials, when unjustified, not only wastes taxpayer money but also compromises patient care and erodes public trust in regenerative medicine.”
Implications for Compliance, Clinics, and Patients
This case underscores the importance of robust compliance protocols, especially for practices offering advanced wound care. Medical directors and billing departments must ensure strict adherence to Medicare’s Local Coverage Determinations (LCDs), accurate clinical documentation, and physician supervision during procedures.
Patients, particularly Medicare beneficiaries, are urged to regularly review their Explanation of Benefits (EOBs) and to report any treatments or procedures they do not recognize. Advocacy organizations may also need to invest more in educating patients about their rights and responsibilities under Medicare.
The long-term impact of this case could include:
- More aggressive post-payment audits on skin substitute claims
- Greater scrutiny of podiatric practices with unusually high volume of applications
- Potential manufacturer-level investigations if promotional practices contributed to off-label or fraudulent use
Next Steps in the Legal Process
Jenson and Romero have been formally indicted and may face additional federal charges as the investigation continues. If convicted, they could be sentenced to decades in federal prison and be required to repay tens of millions of dollars to the Medicare program. Investigators are also reviewing whether employees or third-party suppliers were involved in the scheme.
In the meantime, the case serves as a stark warning: the misuse of advanced wound care technologies not only jeopardizes public funds but may threaten the future availability of these tools for patients who genuinely need them.
Keywords: Medicare fraud, skin substitute, wound care compliance, cellular tissue products, DOJ investigation
Editor’s Note: The defendants are presumed innocent until proven guilty. This article reflects public charges and allegations and does not assert guilt.
Results from the interim analysis of a Multicenter Randomized Control Trial (NCT04564443) that has been accepted for presentation this week at the American Diabetes Association annual meeting in New Orleans, showed that weekly debridement using the debritom+ nearly doubled the rate of wound healing from 40% to 72% compared to the use of traditional methods. Also shown was a significant improvement in wound size reduction (87% versus 35%), while also reducing the frequency of infections and complications.
